Novel therapies in streptococcal toxic shock syndrome: Attenuation of virulence factor expression and modulation of the host response

Current Opinion in Infectious Diseases

Volumn 11, Issue 3, 1998, Pages 285-291

  Norrby Teglund, Anna ^a   Stevens, Dennis L ^b,c  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c Boise VA Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; SUPERANTIGEN; VIRULENCE FACTOR;

ATTENUATION; BACTERIAL GROWTH; BACTERIAL VIRULENCE; CYTOKINE PRODUCTION; DISEASE COURSE; GROWTH INHIBITION; HUMAN; IMMUNE RESPONSE; INFLAMMATION; MORTALITY; PATHOGENESIS; REVIEW; STREPTOCOCCUS GROUP A; STREPTOCOCCUS INFECTION; TOXIC SHOCK SYNDROME;

EID: 0031814402     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-199806000-00004     Document Type: Review

References (58)

1. Stevens DL. Invasive group A streptococcal infections. Clin Infect Dis 1992; 14:2-13.
2. Demers B, Simor AE, Vellend H, Schlievert PM, Byrne S, Jamieson F, et al. Severe invasive group A streptococcal infections in Ontario, Canada: 1987-1991. Clin Infect Dis 1993; 16:792-800.
3. Davies DH, McGeer A, Schwartz B, Green K, Cann D, Simor AE, Low DE, the Ontario Group A Streptococcal Study Group. Invasive group A streptococcal infections in Ontario, Canada. N Engl J Med 1996; 335:547-554.
4. Kiska DL, Thiede B, Caraccido J, Jordan M, Johnson D, Kaplan EL, et al. Invasive group A streptococcal infections in North Carolina: epidemiology, clinical features, and genetic and serotype analysis of causative organisms. J Infect Dis 1997; 176:992-1000. This study describes clinical features and characteristics of isolates from patients with invasive or non-invasive group A streptococcal disease. The authors demonstrate that strains of the same serotype and with identical pulsed field gel electrophoresis patterns can be isolated from both invasive and non-invasive cases. Younger, healthier individuals had the highest incidence of invasive diseases, and the age group from 20-40 years had the highest mortality rate. The authors discuss theories about reservoirs and dissemination of invasive strains.
5. Working Group on Severe Streptococcal Infections. Defining the group A streptococcal toxic shock syndrome. Rationale and consensus definition. JAMA 1993; 269: 390-391.
6. Cockerill FRIII, MacDonald KL, Thompson RL, Roberson F, Kohner PC, Besser-Wiek J, et al. An outbreak of invasive group A streptococcal disease associated with high carriage rates of the invasive clone among school-aged children. JAMA 1997; 277:38-43.
7. Stevens DL, Tanner MH, Winship J, Swartz R, Reiz KM, Schlievert PM, Kaplan E. Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N Engl J Med 1989; 321:1-7.
8. Lancefield RC. Current knowledge of type-specific M antigens of group A streptococci. J Immunol 1962; 89:307-313.
9. Johnson DR, Stevens DL, Kaplan EL. Epidemiologic analysis of group A streptococcal serotypes associated with severe systemic manifestations, rheumatic fever, or uncomplicated pharyngitis. J Infect Dis 1992; 166:372-382.
10. DiPersio JR, File TM, Stevens DL, Gardner WG, Petropoulos G, Dinsa K. Spread of serious disease-producing M3 clones of group A streptococcus among family members and health care workers. Clin Infect Dis 1996; 22:490-495.
11. Kotb M. Bacterial pyrogenic exotoxins as superantigens. Clin Microbiol Rev 1995; 8:411-426.
12. Marrack P, Kappler J. The staphylococcal enterotoxins and their relatives. Science 1990; 248:705-711.
13. Kotb M. Superantigens of Gram-positive bacteria: structure-function analyses and their implication for biological activity. Curr Opin Microbiol 1998; 1:56-65. This is a comprehensive review which includes detailed descriptions of the interaction of superantigens with major histocompatibility complex molecules and the T cell receptor. The biological consequences of these interactions are discussed.
14. Stevens D, Bryant AE, Hackett SP. Sepsis syndromes and toxic shock syndromes: concepts in pathogenesis and a perspective of future treatment strategies. Curr Opin Infect Dis 1993; 6:374-383.
15. Kamezawa Y, Nakahara T, Nakano S, Abe Y, Nozaki-Renard J, Isono T. Streptococcal mitogenic exotoxin Z, a novel acidic superantigenic toxin produced by a T1 strain of Streptococcus pyogenes. Infect Immun 1997; 65:3828-3833.
16. Watanabe-Ohnishi R, Low DE, McGeer A, Stevens DL, Schlievert PM, Newton D, et al., Ontario Streptococcal Study Group. Selective depletion of Vβ-bearing T cells in patients with severe invasive group A streptococcal infections and streptococcal toxic shock syndrome. J Infect Dis 1995; 171:74-84.
17. Levy R, Kotb M, Majumdar G, Alkan A, Ofek I, Beachey EH. Stimulation of oxidative burst in human monocytes by lipoteichoic acid. Infect Immun 1990; 58:566-568.
18. Hackett SP, Stevens DL. Streptococcal toxic shock syndrome: synthesis of tumor necrosis factor and interleukin-1 by monocytes stimulated with pyrogenic exotoxin A and streptolysin O. J Infect Dis 1992; 165:879-885.
19. Herwald H, Collin M, Muller-Esterl W, Björck L. Streptococcal cystein protease releases kinins: a virulence mechanism. J Exp Med 1996; 184:665-673.
20. Shanley TP, Schrier D, Kapur V, Kehoe M, Musser JM, Ward PA. Streptococcal cysteine protease augments lung injury induced by products of group A streptococci. Infect Immun 1996; 64:870-877.
21. Lukomski S, Sreevatsan S, Amberg C, Reichardt W, Woischnik M, Podbielski A, Musser JM. Inactivation of Streptococcus pyogenes extracellular cystein protease significantly decreases mouse lethality of serotype M3 and M49 strains. J Clin Invest 1997; 99:2574-2580. This study demonstrates that streptococcal strains deficient in the expression of streptococcal extracellular cystein protease are significantly less virulent in mice than wild type strains.
22. Lukomski S, Burns EH Jr, Wyde PR, Podbielski A, Rurangirwa J, Moore-Poveda DK, Musser JM. Genetic inactivation of an extracellular cystein protease (SpeB) expressed by Streptococcus pyogenes decreases resistance to phagocytosis and dissemination to organs. Infect Immun 1998; 66:771-776.
23. Kapur V, Majesky MW, Li L-L, Black RA, Musser JM. Cleavage of interleukin 1b (IL-1b) precursor to produce active IL-1b by a conserved extracellular cystein protease from Streptococcus pyogenes. Proc Natl Acad Sci USA 1993; 90:7676-7680.
24. Burns EH Jr, Marciel AM, Musser JM. Activation of 66-kilodarton human endothelial cell matrix metalloprotease by Streptococcus pyogenes extracellular cystein protease. Infect Immun 1996; 64:4744-4750.
25. Blackwell TS, Christman JW. Sepsis and cytokines: current status. Br J Anaesth 1996; 77:110-117.
26. Fischetti VA. The streptococcus and the host. Present and future challenges. Adv Exp Med Biol 1997; 418:15-20.
27. Stevens DL, Bryant-Gibbons AE, Bergstrom R, Winn V. The Eagle effect revisited: efficacy of clindamycin, eryhtromycin, and penicillin in the treatment of streptococcal myositis. J Infect Dis 1988; 158:23-28.
28. Eagle H. Experimental approach to the problem of treatment failure with penicillin. I. Group A streptococcal infection in mice. Am J Med 1952; 13:389-399.
29. Stevens DL, Maier KA, Mitten JE. Effect of antibiotics on toxin production and viability of Closfridium perfringens. Antimicrob Agents Chemother 1987; 31:213-218.
30. Gemmel CG, Peterson PK, Schmeling D, Kim Y, Mathews J, Wannamaker L, Quie PG. Potentiation of opsonization and phagocytosis of Streptococcus pyogenes following growth in the presence of clindamycin. J Clin Invest 1981; 67:1249-1256.
31. Yan S, Bohach GA, Stevens DL. Persistent acylation of high-molecular weight penicillin binding proteins by penicillin induces the post antibiotic effect in Streptococcus pyogenes. J Infect Dis 1994; 170:609-614.
32. Norrby-Teglund A, Pauksens K, Holm SE, Norgren M. Relation between low capacity of human sera to inhibit streptococcal mitogens and serious manifestation of disease. J Infect Dis 1994; 170:585-591.
33. Mouthon L, Kaveri SV, Spalter SH, Lacroix-Desmazes S, Lefranc C, Desai R, Kazatchkine MD. Mechanisms of action of intravenous immune globulin in immune-mediated diseases. Clin Exp Immunol 1996; 104 (Suppl 1):3-9.
34. Ballow M. Mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory diseases. Allergy Clin Immunol 1997; 100:151-157.
35. Shulman ST, Bendet M. Kawasaki disease. Compr Ther 1997; 23:13-18.
36. Barry W, Hudgins L, Donta ST, Pesanti EL. Intravenous immunoglobulin therapy for toxic shock syndrome. JAMA 1992; 267:3315-3316.
37. Mahieu LD, Holm SE, Goossens HJ, Van Acker KJ. Congenital streptococcal toxic shock syndrome with absence of antibodies against streptococcal pyrogenic exotoxins. J Pediatr 1995; 127:987-989.
38. Chieu CH, Lin TY. Successful treatment of severe streptococcal toxic shock syndrome with a combination of intravenous immunoglobulin, dexamethasone and antibiotics. Infection 1997; 25:47-48.
39. Nadal D, Lauener RP, Braegger CP, Kaufhold A, Simma B, Lutticken R, Seger RA. T cell activation and cytokine release in streptococcal toxic shock-like syndrome. J Pediatr 1993; 122:727-729.
40. Lamothe F, D'Amico P, Ghosn P, Tremblay C, Braidy J, Patenaude J-V. Clinical usefulness of intravenous human immunoglobulins in invasive group A streptococcal infections: case report and review. Clin Infect Dis 1995; 21:1469-1470.
41. Perez CM, Kubak BM, Cryer HG, Salehmugodam S, Vespa P, Farmer D. Adjunctive treatment of streptococcal toxic shock syndrome using intravenous immunoglobulin: case report and review. Am J Med 1997; 102:111-113.
42. Yong JM. Necrotizing fasciitis. Lancet 1994; 343:1427.
43. Kaul R, McGeer A, Low DE, Green K, Schwartz B, Simor E, Ontario Group A Streptococcal Study Group. Population-based surveillance for group A streptococcal necrotizing fasciitis: clinical features, prognostic indicators, and microbiologic analysis of seventy-seven cases. Am J Med 1997; 103:18-24. This was a prospective study of group A streptococcal necrotizing fasciitis conducted in Ontario, 1991-1995, which included 77 patients. The authors described demographic, clinical and bacteriological data. The effect of intravenous immunoglobulin as treatment for necrotizing fasciitis was discussed.
44. Kaul R, McGeer A, Norrby-Teglund A, Kotb M, Low DE, Ontario Streptococcal Study Group. Intravenous immunoglobulin (IVIG) therapy in streptococcal toxic shock syndrome (STSS): results of a matched case-control study. In: Abstracts of the 35th Interscience Conference of Antimicrobial Agents and Chemotherapy 1995. Washington DC: American Society for Microbiology; 1995. LM68.
45. Skansen-Saphir U, Andersson J, Björk L, Andersson U. Lymphokine production induced by streptococcal pyrogenic exotoxin-A is selectively down-regulated by pooled human IgG. Eur J Immunol 1994; 24:916-922.
46. Norrby-Teglund A, Kaul R, Low DE, McGeer A, Newton DW, Andersson J, et al. Plasma from patients with severe invasive group A streptococcal infections treated with normal polyspecific IgG (IVIG) inhibits streptococcal superantigen-induced T cell proliferation and cytokine production. J Immunol 1996; 156:3057-3064.
47. Norrby-Teglund A, Kaul R, Low DE, McGeer A, Andersson J, Andersson U, Kotb M. Evidence for the presence of streptococcal-superantigen-neutralizing antibodies in normal polyspecific immunoglobulin G. Infect Immun 1996; 64:5395-5398.
48. Norrby-Teglund A, Low DE, McGeer A, Andersson J, Kotb M. Decreased levels of inflammatory cytokines in patients with severe invasive group A streptococcal infection following IVIG treatment. In: Abstracts of the 4th International Congress on the Immune Consequences of Trauma, Shock and Sepsis. 1997. OP857.
49. Norrby-Teglund A, Basma H, Andersson J, McGeer A, Low DE, Kotb M. Varying titres of neutralizing antibodies to streptococcal superantigens in different preparations of normal polyspecific immunoglobulin G (IVIG): implications for therapeutic efficacy. Clin Infect Dis 1998; 26:631-638. This report demonstrates that there is a large variation between different preparations and lots of IVIG in levels of neutralizing antibodies, and the clinical importance of this finding is discussed. The authors propose ways for the optimization of IVIG therapy in group A streptococcal infections.
50. Fisher GW, Cieslak TJ, Wilson SR, Weisman LE, Heeming VG. Opsonic antibodies to Staphylococcus epidermis: in vitro and in vivo studies using human intravenous immune globulin. J Infect Dis 1994; 169:324-329.
51. Weisman LE, Cruess DF, Fisher GW. Opsonic activity of commercially available standard intravenous immunoglobulin preparations. Pediatr Infect Dis 1994; 13:1122-1125.
52. Basma H, Norrby-Teglund A, Low DE, McGeer A, Dale JB, El-Ahmady O, Kotb M. Opsonic antibodies to the surface M protein of group A streptococci in pooled normal immunoglobulins (IVIG): potential impact on the clinical efficacy of IVIG in severe invasive group A streptococcal infections. Infect Immun 1998; 66:in press.
53. Stevens DL. Could non-steroidal anti-inflammatory drugs (NSAIDs) enhance the progression of bacterial infections to toxic shock syndrome? Clin Infect Dis 1995; 21:977-980.
54. Stevens DL, Hackett S, Bryant AE. Suppression of mononuclear cell synthesis of tumor necrosis factors by azrthromycin. In: Abstracts of the 35th Infectious Disease Society of America Meeting. 1997. 181:105.
55. Stevens DL, Bryant AE, Hackett SP, Chang A, Peer G, Kosanke S, et al. Group A streptococcal bacteremia: the role of tumor necrosis factor in shock and organ failure. J Infect Dis 1996; 173:619-626.
56. Cohen J, Carlet J, International Sepsis Trial Study Group. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha inpatients with sepsis. Crit Care Med 1996; 24:1431-1440.
57. Fisher CJJr, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, et al. The Soluble TNF Receptor Sepsis Study Group. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. N Engl J Med 1996; 334:1697-1702.
58. Fisher CJ Jr, Dhainaut JF, Opal SM, Pribble JP, Balk RA, Slotman GJ, et al. Sepsis Syndrome Study Group. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhlL-1ra. JAMA 1994; 271:1836-1643.